- Home
- MESO vs CNMD Comparison
MESO vs CNMD Comparison
Compare MESO & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- CNMD
- Stock Information
- Founded
- MESO 2004
- CNMD 1970
- Country
- MESO Australia
- CNMD United States
- Employees
- MESO N/A
- CNMD N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MESO Health Care
- CNMD Health Care
- Exchange
- MESO Nasdaq
- CNMD Nasdaq
- Market Cap
- MESO 1.4B
- CNMD 1.7B
- IPO Year
- MESO N/A
- CNMD 1987
- Fundamental
- Price
- MESO $10.64
- CNMD $56.74
- Analyst Decision
- MESO Buy
- CNMD Buy
- Analyst Count
- MESO 4
- CNMD 5
- Target Price
- MESO $18.00
- CNMD $62.20
- AVG Volume (30 Days)
- MESO 226.6K
- CNMD 356.4K
- Earning Date
- MESO 02-26-2025
- CNMD 07-30-2025
- Dividend Yield
- MESO N/A
- CNMD 1.41%
- EPS Growth
- MESO N/A
- CNMD 46.38
- EPS
- MESO N/A
- CNMD 3.81
- Revenue
- MESO $5,670,000.00
- CNMD $1,315,998,000.00
- Revenue This Year
- MESO $178.09
- CNMD $6.27
- Revenue Next Year
- MESO $305.06
- CNMD $5.62
- P/E Ratio
- MESO N/A
- CNMD $14.89
- Revenue Growth
- MESO N/A
- CNMD 4.32
- 52 Week Low
- MESO $5.78
- CNMD $46.00
- 52 Week High
- MESO $22.00
- CNMD $78.58
- Technical
- Relative Strength Index (RSI)
- MESO 40.85
- CNMD 49.66
- Support Level
- MESO $10.60
- CNMD $54.77
- Resistance Level
- MESO $11.26
- CNMD $58.27
- Average True Range (ATR)
- MESO 0.41
- CNMD 1.59
- MACD
- MESO -0.06
- CNMD -0.25
- Stochastic Oscillator
- MESO 12.00
- CNMD 31.22
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.